Abstract:
Introduction. According of American Psychiatric Association,mental health is defined by the
simultaneous success in work, love and the ability to resolve with maturity and flexibility the
conflict between instinct, consciousness, close persons and reality.There is no universal
definition.However, neuropsychiatric disorders are the third cause of disability in Europe and
represent 15.2%, after cardiovascular disease 26.6% and malignant neoplasms (cancers)
15.4%.The most common mental illnesses are anxiety, depression and dementia.It is estimated
that by 2020 depression will become the second leading cause of disability worldwide, after
cardiovascular diseases.
Aim of the study. In this study we have proposed as the objective the recipe of the medical
scientific literature of the contemporary therapy of depressive states.
Materials and methods. The bibliographic and informative sources published in recent years,
published both internationally and in the Republic of Moldova, have been used as study
materials.
Results. Scientific dates demonstrate that treatment of depressive states includes several groups
of preparations: selective serotonin reuptake inhibitors (SSRIs),noradrenaline and dopamine
reuptake inhibitors (IRND),selective serotonin reuptake enhancers (SSRIs),noradrenergic and
serotoninergic antidepressants,serotonin and noradrenaline reuptake inhibitors (IRSN),
monoamine oxidase inhibitors (MAOIs),tranquilizing benzodiazepines and nonbenzodiazepine.
Of the classes of organic substances with MAO inhibitors are involved and
derivatives of 2-indolinone and 2,3-indolinedione.In this context, a new autohtone compound of
the isatine group is investigated, with pronounced antidepressant and sedative-tranquilizing
activity–1'-(2-oxo-propyl)-spiro[[1,3]dioxolane-2',3'-indolin]-2'-one with the common name
"DIOXOINDOLINONE" synthesized in the Organic Synthesis and Biopharma- ceutical
Laboratory of the Institute of Chemistry.
Conclusions. Although there are already a large number of antidepressant drugs in the
pharmaceutical market, the development of new structures remains in the topicality.
